Overview

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Status:
Recruiting
Trial end date:
2040-04-30
Target enrollment:
Participant gender:
Summary
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bellicum Pharmaceuticals
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate